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Since the start of the epidemic some two decades ago, ffiV has
infected more than 47 million people and has claimed the lives
of nearly 14 million adults and children. According to estimates
from UNAIDS and the World Health Organisation, some 33
million people were living with ffiV and AIDS by the end of
1999. Of these, more than 3 million were South Africans. Africa,
and in particular Sub-Saharan Africa, has become the global
epicentre of the epidemic. As the seroprevalence of ffiV among
pregnant women attending public antenatal clinics is 22/100,
many newborns are at psk of ffiV.' In the absence of
programmes to prevent mother-to-child transmission,
approximately 50 000 ffiV-1-infected babies are born each year
in South Africa.
In 1994 the Pediatric AIDS Clinical Trials Group (PACTG)
076 trial demonstrated the efficacy of zidovudine (ZDV) in
reducing mother-to-ehild transmission (MTCT) of ffiV-1 from
25.5% to 8.3%.2 This regimen included administration of ZDV
orally 5 times daily from late mid-trimester, intravenously
during labour, and then to the exposed neonate. In 1998 a
simplified regimen from Thailand showed that oral ZDV given
twice daily from 36 weeks gestational age could also reduce
transmission risk by 51% (18.9% to 9.4%).3 By this time the
importance of ZDV as post-exposure prophylaxis had been
demonstrated in health care workers exposed to percutaneous
injury," an extrapolation of which suggested that postnatal ZDV
might be important for the ffiV-exposed neonate.
Aid for AIDS (MA) is a disease management programme
offered by Pharmaceutical Benefit Management (PBM) and
Medscheme Integrated Care Division to members of contracted
medical aid schemes for the management of ffiV. It has been
operational since June 1998 and to date over 5000 members
benefit from the programme, which includes provision for a
unique vertical transmission prophylaxis (VTP) regimen. We
now report our preliminary results on the efficacy of this
regimen.
METHODS
Vertical transmission prophylaxis and diagnosis of
HIV infection in the neonate
We adopted the simplified ZDV regimen from Thailand, but
permitted a dosage of 250 mg noVice daily instead of 300 mg,
thus allowing a single tablet instead of 3 tablets to be
administered, as we felt that this would promote compliance.
ZDV was provided from 36 weeks gestational age. During
labour ZDV was given either as a continuous intravenous
infusion, or per 05 3-hourly. The newborn received ZDV
suspension for 6 weeks at a dosage of 2 mg/kg 4 times a day.
Elective caesarean section and formula feeds were funded by
the programme and actively encouraged. A qualitatj.ve
polymerase chain reaction (PCR) assay for ffiV-1 DNA or RNA
was performed on exposed infants after 6 weeks of age, and if
positive was regarded as evidence of infection.
We defined incomplete VTP as either inadequate (less than 2
weeks) ZDV given to the mother or the absence of post-
exposure prophylaxis to the exposed infant. Complete VTP was
defined as the mother receiving at least 2 weeks of ZDV prior
to delivery and the neonate a 6-week course of ZDV
suspension.
Data analysis
Women eligible for VTP were identified through confidential
application to AfA. Data were evaluated from June 1998
through February 2000. A telephonic interview with the mother
was conducted by a registered nurse employed by MA. The
method of delivery, use of formula feeds and the PCR result
were obtained. Where possible confirmatory laboratory results
. were obtained.
RESULTS
During the period tinder review, 412 pregnant women
registered with the programme. By the end of February 2000,
278 deliveries were recorded. The majority (approximately
80%) were delivered by elective caesarean section. The
transmission rate in those completing the VTP protocol was
3.4% (4 of 116). The complete analysis of available data is
shovvn in the accompanying organogram (Fig. 1). Of 89
members receiving either incomplete or no VTP, data were
available on 15 infants, of whom 8 were infected.
DISCUSSION I •
The data confirm the efficacy of the AfA VTP programme, as
the transmission rate was only 3.4%. In the absence of
intervention, vertical transmission may occur in between 18%
and 30%? These data suggest an improvement on both the
PACTG 076 and Thai-CDC studies, where transmission was
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Fig. 1. Organogram illustrating the outcome of the pregnancies of278 HIV-infected mothers registered with the Aid for AIDS programme
(VTP =vertical transmission prophylaxis; Incomplete VTP = inadequate (less than 2 weeks) ZDV given to the mother or the absence of post-
exposure prophylaxis to the exposed infant; Complete VTP = at least 2 weeks of ZDV to the mother prior to delivery, and a 6-week course ofZDV
suspension to the neonate).
reduced to 8.3% and 9.1%, respectively. A recent meta-analysis
showed that elective caesarean section alone could reduce the
transmission rate by 50% (16.7% to 8.2%) and to 2% if
combined with antiretroviral therapy.'
A shortcoming of our analysis is that it did not take place in
the context of a study, but rather reflected 'real-life' experience,
We relied on telephonic interviews and often experienced
difficulty in communicating with members. Approximately
80% of women underwent an elective caesarean section.
Another potential problem was that we did not obtain a second
confirmatory PCR assay in exposed infants. This is of relevance
for infants being breast-fed as RN transmission may occur at a
later date.
Of particular concern is the lack of data in women who did
not receive complete VTP. Of 89 women in this group, only 15
could be contacted. Eight of 15 infants were infected.
Our VTP regimen combined the simplicity of the Thai-OX
protocol and the postnatal arm of the PACTG 076 study, as we
considered that post-exposure prophylaxis might compensate
for abbreviated periods of antenatal ZDV administration,
especially if it was for less than 4 weeks' duration. The
importance of postnatal ZDV was confirmed in a recent study
by Wade et al./ where postnatal ZDV alone resulted in a 50%
reduction in transmission.'
In conclusion, we have demonstrated the efficacy of the AfA
VTP regimen and provide the first data on the prevention of
mother-to-child transmission from a managed care setting in
Africa.
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